SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the launch of its Decipher Prostate Metastatic Genomic ...
The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...
Findings are from the multicenter, prospective, Phase 3 STAMPEDE trial “Our findings suggest that the Decipher Prostate test may provide an important new tool to help guide treatment decisions for the ...
Veracyte, Inc., a leading cancer diagnostics company, today announced that data from its market-leading Decipher Prostate Genomic Classifier are available in a new specialized database that the ...
More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests "The breadth of data at ASCO GU ...
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the ...
The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed ...
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in Cell show that the Decipher Prostate Genomic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results